Novartis: positive phase 2 results in kidney disease

(CercleFinance.com) - On Monday Novartis announced positive results from a Phase 2 clinical study of a new class of drugs for C3 glomerulopathy, a kidney disease.


The study found that the new drug, called iptacopan, reduced proteinuria, the presence of protein in the urine, by 49% after 12 weeks of treatment.

Novartis says that abnormal proteinuria is a sign of inflammation of the kidneys.

Iptacopan is also being tested clinically in nephrology, particularly for immunoglobulin A (IgA) nephropathy and paroxysmal nocturnal haemoglobinuria.


Copyright (c) 2020 CercleFinance.com. All rights reserved.